SAMSUNG
23.2.2021 11:02:14 CET | Business Wire | Press release
Samsung Electronics Co., Ltd., a world leader in advanced semiconductor technology, today introduced Samsung ISOCELL GN2, a new 50-megapixel (Mp) image sensor with large 1.4-micrometer (μm)-sized pixels. With enhancements to its predecessor, the ISOCELL GN1, the GN2 offers up to 100Mp imaging, improved auto-focusing through Dual Pixel Pro technology, powerful staggered HDR, and vivid results through Smart ISO Pro, regardless of the lighting environment.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210223005475/en/
“ISOCELL image sensors and its technologies have made vast improvements to deliver the quality and performance one would expect from top-tier prograde cameras,” said Duckhyun Chang, executive vice president of sensor business at Samsung Electronics. “Our new ISOCELL GN2 features Dual Pixel Pro, an innovative all-direction auto-focusing solution that elevates the agility to capture moments as they unfold. Adding on Smart ISO Pro and a variety of advanced pixel technologies, pictures from GN2 are more true-to-life than ever.”
The 1/1.12-inch ISOCELL GN2 is a highly versatile image sensor when it comes to image resolutions. With 50 million 1.4μm-sized pixels on hand, the GN2 offers exceptionally detailed photographs in regular settings. In low-lit environments such as indoors, the sensor can simulate a larger 2.8μm-pixel with four-pixel-binning technology to absorb more light, delivering brighter and sharper images.
For those who appreciate more detail in photographs or are prone to post-processing such as image cropping, the GN2 offers an option to take pictures in 100Mp resolutions. In 100Mp mode, the GN2 meticulously re-arranges the color pixels using an intelligent re-mosaic algorithm, creating three individual layers of 50Mp frames in green, red and blue. These frames are then up-scaled and merged to produce a single ultra-high 100Mp resolution photograph.
The ISOCELL GN2 is Samsung’s first image sensor to offer Dual Pixel Pro, the company’s most advanced phase-detection auto-focus solution yet. By employing two photodiodes within every pixel of the image sensor, Dual Pixel Pro makes use of one hundred million phase detecting agents for ultra-fast auto-focusing. In addition, the solution also offers all-direction focusing by splitting the pixels not only vertically, as with Dual Pixel, but also diagonally. This diagonal cut allows the focusing agents to better recognize the top and bottom of the frame, allowing the sensor to get in focus quickly even when there are no pattern changes in a horizontal direction. Low-light focusing and tracking of moving objects are improved as well, as every pixel of the sensor works as focusing agents.
For taking pictures in mixed-light environments, such as sunsets or indoors with daylight coming through a window, the GN2 increases its dynamic range with a staggered-HDR feature, a time-multiplexed HDR technology that uses rolling shutters over the same pixel arrays to capture multiple frames in short, middle, and long exposures. By maximizing the dynamic range, staggered-HDR ensures rich detail and vivid color in highlights and dark shadows within the scene, making it an ideal solution for shooting high-contrast sights. Staggered-HDR is able to reduce the energy consumption of a sensor by up to 24-percent when compared to the predecessor’s real-time HDR mode, contributing to improved energy efficiency of the overall system.
The GN2 also comes with Smart ISO and Smart ISO Pro. Smart ISO intelligently sets the sensor’s conversion gain, allowing the picture to be taken using an optimal ISO; low ISO for brighter outdoors or high for dimmer indoors. Unlike Smart ISO, which uses readouts from a single ISO per picture, Smart ISO Pro, which uses an intra-scene dual conversion gain (iDCG) solution, takes readouts from both high and low ISO to instantly create high dynamic range images with less motion-artifacts. In addition, in extreme low-light, Smart ISO Pro quickly takes and processes multiple frames in high ISO, raising the light sensitivity close to one-million ISOs and taking mobile night photography to greater heights.
Camera experiences can be more fun and creative with the GN2, where precious moments can be captured more dramatically and everyday events can be turned into short videos. The GN2 supports full-HD videos at 480 frames-per-second (fps) or 4K at 120fps, enabling wider possibilities for mobile video-shooting.
Samsung ISOCELL GN2 is currently in mass production.
About Samsung Electronics Co., Ltd.
Samsung inspires the world and shapes the future with transformative ideas and technologies. The company is redefining the worlds of TVs, smartphones, wearable devices, tablets, digital appliances, network systems, and memory, system LSI, foundry and LED solutions. For the latest news, please visit the Samsung Newsroom at http://news.samsung.com .
# # #
* Samsung first announced its ISOCELL technology in 2013, which reduces color crosstalk between pixels by placing a physical barrier, allowing small-sized pixels to achieve higher color fidelity. Based on this technology, Samsung introduced the industry’s first 1.0μm-pixel image sensor in 2015 and a 0.9-pixel sensor in 2017. Samsung continues to enhance its pixel isolation methods with ISOCELL Plus and the ISOCELL 2.0 technologies.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210223005475/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Europe’s Largest Celebration of Irish Culture Arrives in Belfast2.8.2026 10:01:00 CEST | Press release
Fleadh Cheoil na hÉireann arrives in Belfast today (2 August), bringing eight days of traditional music, culture and celebration to the city, with organisers expecting up to 800,000 visitors over the course of the festival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260729147569/en/ Belfast Fleadh - Maddens Bar accordian, guitar and fiddle player (Chris Heaney) One of Europe’s largest cultural events, Fleadh Cheoil na hÉireann is taking place in Belfast for the first time, transforming the city into a vibrant stage for Irish music, dance, language and culture. More than 200 events and 180 traditional music competitions are taking place across venues, streets and neighbourhoods throughout the week-long celebration. The landmark festival showcases the very best of Irish culture, with a packed programme of All-Ireland competitions, concerts, community events and performances from both established and emerging artists. As Ir
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom